Picard Medical, Inc. Announces Presentation at H.C. Wainwright Global Investment ConferenceGlobeNewswireSeptember 08, 2025TUCSON, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard" or the "Company"), today announced that Patrick NJ Schnegelsberg, Chief Executive Officer, will present in-person at the H.C. Wainwright 27th Annual Global Investment Conference being held both in-person and virtually from September 8 -10, 2025 at the Lotte New York Palace Hotel.
Presentation information is below:
H.C. Wainwright Annual Global Investment Conference
Presentation date: September 10thPresentation time: 1:30 pm Format: in-person; live, webcasted Company presentation with reply
To listen to the presentation live or via replay, please visit the Investor Overview/Events section of the Picard website here
About Picard Medical, Inc.
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart ("STAH"), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com.
Contact:
Investors
Eric RibnerManaging DirectorLifeSci Advisors LLCeric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLCIR@picardmedical.com
General/Media
Brittany Lanzablanza@syncardia.com
COMTEX_468629021/2010/2025-09-08T07:00:04
TUCSON, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard" or the "Company"), today announced that Patrick NJ Schnegelsberg, Chief Executive Officer, will present in-person at the H.C. Wainwright 27th Annual Global Investment Conference being held both in-person and virtually from September 8 -10, 2025 at the Lotte New York Palace Hotel.
Presentation information is below:
H.C. Wainwright Annual Global Investment Conference
Presentation date: September 10thPresentation time: 1:30 pm Format: in-person; live, webcasted Company presentation with reply
To listen to the presentation live or via replay, please visit the Investor Overview/Events section of the Picard website here
About Picard Medical, Inc.
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart ("STAH"), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com.
Contact:
Investors
Eric RibnerManaging DirectorLifeSci Advisors LLCeric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLCIR@picardmedical.com
General/Media
Brittany Lanzablanza@syncardia.com
COMTEX_468629021/2010/2025-09-08T07:00:04
19.01% $0.77
